Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has announced the cessation of several securities, including options that have expired or lapsed due to unmet conditions. This announcement reflects a routine adjustment in the company’s capital structure, which may influence investor perceptions and the company’s financial strategy moving forward.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company is dedicated to advancing a range of novel cancer immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors.
Average Trading Volume: 23,323,994
Technical Sentiment Signal: Sell
Current Market Cap: A$156.8M
Learn more about IMU stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue